P-D-R Pharma Documentation Ring

The P-D-R is an association whose members represent the scientific information departments of the leading international R&D-based pharmaceutical corporations.

Latest News from the P-D-R Company Websites

Published 18 November 2019 | 10:01 pm

HOW YOU CAN HELP SLOW THE THREAT OF ANTIMICROBIAL RESISTANCE

Before antibiotics were discovered in the 20th century, contracting an infection could be a death sentence. Their discovery was a turning point in human history, revolutionizing more ...

Published 18 November 2019 | 2:21 pm

Can AI reinvent drug design?

For more than 90 years, UCB has been dedicated to research and innovation. Our medicines have helped to improve the lives of people around the world living with severe more ...

Published 18 November 2019 | 1:56 pm

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 18 November 2019 - On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 more ...

Published 18 November 2019 | 1:38 pm

The Roche pRED Innovation Centres

more ...

Published 18 November 2019 | 1:11 pm

FDA Approves Pfizer's Biosimilar, ABRILADATM (adalimumab-afzb) for Multiple Inflammatory Conditions

Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADATM more ...

Published 18 November 2019 | 12:48 pm

Dicerna and Novo Nordisk enter agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases

Collaboration to explore liver cell targets using Dicerna's GalXCTM technology with the potential to deliver a significant number of clinical candidates more ...

Published 18 November 2019 | 9:47 am

Transforming Humanitarian Aid in Hemophilia

About us All Our Stories Transforming Humanitarian Aid in Hemophilia more ...

Published 18 November 2019 | 7:25 am

Investor Update

more ...

Published 17 November 2019 | 5:42 pm

Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

- This analysis on effectiveness also shows Jardiance® (empagliflozin) was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 more ...

Published 17 November 2019 | 4:54 pm

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan 1 more ...

Pharma Documentation Ring:
26 companies - 4 common aims:

  • Promote exchange of experience/networking among members
  • Encourage commercial development of new information services and systems
  • Jointly assess new and existing products and services
  • Provide a forum for the information industry
  • How to become a P-D-R member?
61st P-D-R Annual General Meeting, Summit, NJ, USA, September 17 - 20 2019

61st P-D-R Annual General Meeting, Summit, NJ, USA, September 17 - 20 2019